ACTU
Actuate Therapeutics Inc (ACTU) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
No disclosed R&D intensity or capital-allocation evidence is provided, limiting assessment of whether ACTU is ahead of peers on low-carbon or resource-efficiency initiatives.
Zero reported gross profit margin in the supplied metrics suggests limited operating headroom for environmental investment versus peers, though this is not direct ESG evidence.
The provided data do not show emissions, energy, water, or waste disclosures, so ACTU cannot be credited for environmental transparency relative to better-disclosing peers.
Absent sustainability metrics, ACTU appears broadly middle-of-pack on environmental positioning, with no clear advantage or structural disadvantage versus peers.
Social
No workforce, safety, turnover, or diversity disclosures are provided, which weakens evidence that ACTU manages social risks as well as more transparent peers.
Zero stock-based compensation in the metrics may indicate lower dilution pressure, but it does not directly demonstrate stronger employee alignment or retention versus peers.
The absence of customer, product, or community impact metrics prevents a stronger social assessment, leaving ACTU comparable to peers with similarly limited disclosure.
Overall social positioning appears neutral rather than differentiated, because the available data show neither clear social strengths nor material controversies.
Governance
Debt-to-equity of 0.41 and net debt-to-EBITDA of 0.20 indicate relatively conservative leverage, which usually supports governance discipline versus more levered peers.
Zero stock-based compensation in the supplied metrics suggests restrained equity dilution, which can align management incentives more cleanly than peers with heavier SBC usage.
However, the dataset lacks board independence, audit, ownership, and controversy information, so ACTU cannot be assessed as a governance leader relative to peers.
On the available evidence, ACTU’s governance profile is modestly better than average on capital discipline, but not strong enough to indicate top-tier oversight.
Overall Score
ACTU appears broadly middle-of-pack versus peers because the available data show some governance discipline but insufficient ESG disclosure to establish stronger environmental or social positioning.
Score Driver: Limited ESG Disclosure Across Environmental And Social Dimensions
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Actuate Therapeutics Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
